New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Parnate
Synonyms :
tranylcypromine
Class :
Antidepressants and antianxiety drugs; MAO inhibitors
Brand Name :
Parnate
Synonyms :
tranylcypromine
Class :
Antidepressants and antianxiety drugs; MAO inhibitors
Dosage forms & Strengths:Â
Adult:Â
Tablet:Â
10 mgÂ
Indicated in patients who are irresponsive to other antidepressants
15 mg orally every 12 hours; increase the dose by 5 mg/dose every 1-3 weeks to obtain a sufficient response
Do not exceed the dose of more than 60 mg/day
Once the response gets adequate, slowly decrease the dose
Dosage Forms & StrengthsÂ
TabletÂ
10mgÂ
Indicated in depression, with significant episodes without melancholia
15 mg orally every 12 hours; increase the dose by 5 mg/dose; every 1-3 weeks
Do not exceed more than 60 mg per day
Once the response gets adequate, slowly decrease the dose
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may increase the serotonergic effects
may increase the serum concentration
may enhance serum concentrations when combined with tetrabenazine
may enhance the serum concentration when combined with fenfluramine
may enhance the serum concentration when combined with fenfluramine
may diminish the serum concentration when combined with CYP2D6 substrates
may enhance the serum concentration
may increase the serum concentration of Rasagiline
may enhance the concentration of serum when combined with theophylline derivatives
may enhance the concentration of serum when combined with thioridazine
pirfenidone: they may enhance the serum concentration of CYP1A2 Inhibitors
pomalidomide: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may increase the risk of hypertension when combined
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
may have an increasingly adverse effect when combined with MAO inhibitors
arginine: they may enhance the serum concentration of CYP2D6 Inhibitors
nicardipine: they may enhance the serum concentration of CYP2D6 Inhibitors
brimonidine: they may enhance the serum concentration of CYP2D6 Inhibitors
cimetidine: they may enhance the serum concentration of CYP2D6 Inhibitors
clopidogrel: they may enhance the serum concentration of CYP2D6 Inhibitors
dapoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
diazoxide: they may enhance the serum concentration of CYP2D6 Inhibitors
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
amitriptylinoxide(Phase 4 Clinical Trials)Â
may increase the pharmacodynamic effect of each other when combined
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
brexpiprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
pitolisant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
may enhance the risk of CNS depression when combined with each other
may enhance the risk of CNS depression when combined with each other
caplacizumab: they may enhance the serum concentration of CYP2D6 Inhibitors
cilostazol: they may enhance the serum concentration of CYP2D6 Inhibitors
eliglustat: they may enhance the serum concentration of CYP2D6 Inhibitors
dextroamphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
enoxaparin: they may enhance the serum concentration of CYP2D6 Inhibitors
gilteritinib: they may enhance the serum concentration of CYP2D6 Inhibitors
fluoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
oxycodone: they may enhance the serum concentration of CYP2D6 Inhibitors
lomitamide: they may enhance the serum concentration of CYP2D6 Inhibitors
safinamide: they may enhance the serum concentration of CYP2D6 Inhibitors
may increase the efficacy of each other when combined
inhibitors of the cytochrome P450 enzyme system, like ketoconazole and clarithromycin, have the potential to enhance the exposure and toxicity of rimonabant since it undergoes liver metabolism mediated by this enzyme system
there is a danger of serotonin syndrome; thus, avoid using this product in patients receiving MAOIs or within two weeks or after stopping MAOI treatment
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of hypertension of alpha 1-agonists
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased hypertensive effect when combined with alpha1-agonists
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of SSRIs
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of SSRIs
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may increase the hypertension effect of alfa one agonist
may increase the adverse effect of sympathomimetic drugs
they increase the concentration of alosetron in the serum
may increase the toxic effects of CNS depressants
may increase the serotonergic effect of tricyclic antidepressants
buprenorphine increases the toxicity of MAO inhibitors
acrivastine and pseudoephedrineÂ
may increase the hypertensive effects of alpha/beta agonists
may decrease the hypertensive effect of amphetamines
methyldopa/hydrochlorothiazideÂ
may increase the toxic effect of methyldopa
may have an increased adverse effect when combined with monoamine oxidase inhibitors
they decrease the concentration of active metabolites of iloperidone in the serum
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increasingly adverse effect when combined with codeine
may increase the toxic effect of carbinoxamine
buspirone increases the serotonergic effect of MAO inhibitors
may increase the serotonergic effect
promethazine/dextromethorphanÂ
may increase the serotonergic effect of Dextromethorphan
may have an increasingly adverse effect when combined with isometheptene
may enhance the serum concentration when combined
may increase the adverse effect of Buprenorphine
buprenorphine,long-acting injectionÂ
may increase the adverse effect of Buprenorphine
acetaminophen/doxylamine/dextromethorphanÂ
may increase the serotonergic effect of dextromethorphan
metoclopramide increases the effect of hypertension of MAO inhibitors
may diminish the concentration of serum when combined with CYP1A2 substrates
agomelatine: they may enhance the serum concentration of CYP1A2 Inhibitors
duloxetine: they may enhance the serum concentration of CYP1A2 Inhibitors
melatonin: they may enhance the serum concentration of CYP1A2 Inhibitors
mexiletine: they may enhance the serum concentration of CYP1A2 Inhibitors
viloxazine: they may enhance the hypertensive effect of monoamine oxidase inhibitors
ramelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
tasimelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
may increase the hypertensive effect of Monoamine Oxidase Inhibitors
may have an increased risk of serotonin syndrome when combined with kratom
may increase the serum concentration of each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
they increase the toxicity of bezafibrate
may have an increased hypertensive effect when combined with alpha1-agonists
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
MAO inhibitors increase the effect of hypertension of amphetamines
it increases the toxicity of MAO inhibitors
it enhances the serotonergic effect of MAO inhibitors
MAO inhibitors increase the toxic or adverse effects of hydromorphone
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
sincalide: they may enhance the serum concentration of CYP2D6 Inhibitors
obinutuzumab: they may enhance the serum concentration of CYP2D6 Inhibitors
apraclonidine: it may increase the toxic effect of monoamine oxidase inhibitors A
apraclonidine: it may increase the toxic effect of monoamine oxidase inhibitors
doxorubicin: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
aclidinium: they may enhance the serum concentration of CYP2D6 Inhibitors
bromopride: they may enhance the serum concentration of CYP2D6 Inhibitors
cimetropium: they may enhance the serum concentration of CYP2D6 Inhibitors
glycopyrrolate: they may enhance the serum concentration of CYP2D6 Inhibitors
ipratropium: they may enhance the serum concentration of CYP2D6 Inhibitors
levosulpiride: they may enhance the serum concentration of CYP2D6 Inhibitors
mavacamten: they may enhance the serum concentration of CYP2D6 Inhibitors
olopatadine: they may enhance the serum concentration of CYP2D6 Inhibitors
rasagiline: they may enhance the serum concentration of CYP2D6 Inhibitors
selegiline: they may enhance the serum concentration of CYP2D6 Inhibitors
the effect of brompheniramine may be increased
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood glucose lowering effects
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
it increases the effect of serotonergic agents
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may enhance the tachycardic effect
may enhance the tachycardic effect
may enhance the tachycardic effect
may enhance the tachycardic effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
may enhance the effect of serotonergic activity
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
Monoamine Oxidase Inhibitors: they may increase the toxic effect of Beta2-Agonists
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increased hypoglycemic effect when combined with hypoglycemic agents
It may enhance the risk of adverse effects when combined with monoamine oxidase
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increased serotonergic effect when combined with tricyclic antidepressants
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
monoamine oxidase inhibitor: they may increase the hypertensive effect of Alpha2-Agonists
systemic beta blockade is shown when CYP2D6 inhibtors are combined in use with antiglaucoma agents
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may enhance the serum concentration
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
may increase the toxic effect
may decrease the level of serum concentration of pretomanid
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
may enhance the adverse/toxic effect of MOA inhibitors
linezolid may enhance the serotonergic effect of MAO inhibitors
may increase the serum concentration
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the toxic effect of beta2 agonists
may increase the serum concentration of amphetamines
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may enhance the serum concentration when combined with CYP2D6 substrates
may enhance the serum concentrations of CYP2D6 inhibitors
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the QTc prolonging effect of QTc prolonging agents
may diminish the serum concentration of Lidocaine
promethazine/dextromethorphanÂ
may increase the serum concentration of Dextromethorphan
may have an increased hypertensive effect when combined with norepinephrine
may increase the levels of serum concentration
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
may enhance the concentration of serum when combined with timolol
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
clozapine: they may enhance the serum concentration of CYP1A2 Inhibitors
may enhance the concentration of serum when combined with asenapine
It may increase the hypertensive effect when combined with epinephrine (Systemic)
acetaminophen/doxylamine/dextromethorphanÂ
may enhance the serum concentration when combined
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
empagliflozin and linagliptinÂ
may increase the hypoglycaemic effect with blood glucose lowering agents
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the adverse effect when combined
may increase the levels of serum concentration
may enhance the serum concentration when combined
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
bromazepam: they may enhance the serum concentration of CYP1A2 Inhibitors
clomipramine: they may enhance the serum concentration of CYP1A2 Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
olanzapine: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
riluzole: they may enhance the serum concentration of CYP1A2 Inhibitors
ropinirole: they may enhance the serum concentration of CYP1A2 Inhibitors
ropivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
may affecting the metabolism and increase the side effects when combined with kratom
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
may enhance the QTc-prolonging effect of each other when combined
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
mazindol increases the effect of hypertension when taken with MAO inhibitors
MAO inhibitors increase the anticholinergic action of clemastine
MAO inhibitors increase the anticholinergic action of doxylamine
it increases the effect of hypertension on MAO inhibitors
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
amitriptyline: they may enhance the serum concentration of CYP2D6 Inhibitors
amoxapine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
clomipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
clozapine: they may enhance the serum concentration of CYP2D6 Inhibitors
codeine: they may enhance the serum concentration of CYP2D6 Inhibitors
rolapitant: they may enhance the serum concentration of CYP2D6 Inhibitors
desipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
deutetrabenazine: they may enhance the serum concentration of CYP2D6 Inhibitors
doxepin: they may enhance the serum concentration of CYP2D6 Inhibitors
flecainide: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
oliceridine: they may enhance the serum concentration of CYP2D6 Inhibitors
propafenone: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
protriptyline: they may enhance the serum concentration of CYP2D6 Inhibitors
tamsulosin: they may enhance the serum concentration of CYP2D6 Inhibitors
tramadol: they may enhance the serum concentration of CYP2D6 Inhibitors
valbenazine: they may enhance the serum concentration of CYP2D6 Inhibitors
vortioxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
amifostine: they may enhance the serum concentration of CYP2D6 Inhibitors
flunarizine: they may enhance the serum concentration of CYP2D6 Inhibitors
melatonin: they may enhance the serum concentration of CYP2D6 Inhibitors
molsidomine: they may enhance the serum concentration of CYP2D6 Inhibitors
dimercaprol: they may enhance the serum concentration of CYP2D6 Inhibitors
levonorgestrel: they may enhance the serum concentration of CYP2D6 Inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
quinidine: they may enhance the serum concentration of CYP2D6 Inhibitors
butchers broom: they may enhance the serum concentration of CYP2D6 Inhibitors
finerenone: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
ephedrine: they may enhance the serum concentration of CYP2D6 Inhibitors
kaolin: they may enhance the serum concentration of CYP2D6 Inhibitors
verteporfin: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
vitamin K1: they may enhance the serum concentration of CYP2D6 Inhibitors
triazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
chlormethiazole: they may enhance the serum concentration of CYP2D6 Inhibitors
flunitrazepam: they may enhance the serum concentration of CYP2D6 Inhibitors
nalmefene: they may enhance the serum concentration of CYP2D6 Inhibitors
suvorexant: they may enhance the serum concentration of CYP2D6 Inhibitors
zolpidem: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
samidorphan: they may enhance the serum concentration of CYP2D6 Inhibitors
naltrexone: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
kava: they may enhance the serum concentration of CYP2D6 Inhibitors
metyrosine: they may enhance the serum concentration of CYP2D6 Inhibitors
piribedil: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
belzutifan: they may enhance the serum concentration of CYP2D6 Inhibitors
cannabis: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
etravirine: they may enhance the serum concentration of CYP2D6 Inhibitors
inotersen: they may enhance the serum concentration of CYP2D6 Inhibitors
lithium: they may enhance the serum concentration of CYP2D6 Inhibitors
metoprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
nifedipine: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
perampanel: they may enhance the serum concentration of CYP2D6 Inhibitors
quetiapine: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
quinagolide: they may enhance the serum concentration of CYP2D6 Inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
may have an increased serotonergic effect when combined with serotonin/norepinephrine reuptake inhibitors
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when MAOIs used in combination
induction of these enzymes is shown by bupleurum at high doses
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the efficacy of sympathomimetic drugs
they increase the concentration of metoclopramide in the serum
they decrease the concentration of active metabolites of tamoxifen in serum
MAO inhibitors increase the toxic or adverse effects of reserpine
MAO inhibitors increase the serotonergic effect of lithium
MAO inhibitors increase the toxic or adverse effects of hydrocodone
benzhydrocodone/acetaminophenÂ
it increases the serotonergic effect of MAO inhibitors
Actions and Spectrum:Â
tranylcypromine is a monoamine oxidase inhibitor (MAOI) primarily used to treat major depressive disorder. It works by inhibiting the activity of monoamine oxidase, an enzyme that breaks down neurotransmitters such as serotonin, norepinephrine, and dopamine. This results in increased levels of these neurotransmitters in the brain, which can help alleviate depressive symptoms.Â
The spectrum of actions of tranylcypromine includes:Â
Frequency not definedÂ
DrowsinessÂ
Sleep disturbanceÂ
FatigueÂ
Orthostatic hypotensionÂ
DizzinessÂ
HeadacheÂ
WeaknessÂ
TremorÂ
HyperreflexiaÂ
ConfusionÂ
Decreased memoryÂ
NystagmusÂ
ConstipationÂ
Dry mouthÂ
ParesthesiaÂ
AnorexiaÂ
ImpotenceÂ
IrritationÂ
HypomaniaÂ
Hypermetabolic syndromeÂ
Urinary frequency or retentionÂ
AnxietyÂ
ArthralgiaÂ
EdemaÂ
SIADHÂ
JaundiceÂ
Visual disturbance Â
AtaxiaÂ
SeizureÂ
Black Box Warning:Â
tranylcypromine increases the risk of suicidal thoughts and alters behavior in young adults. The drug is not meant for pediatrics.Â
Contraindication/Caution:Â
tranylcypromine has several contraindications and precautions to be considered before prescribing or taking the medication. These include:Â
Pregnancy consideration:Â Â
No data available for utilization in pregnant womenÂ
Breastfeeding warnings:Â Â
Drug distribution in breast milk is unknown, so use the drug cautiously during lactation.Â
Pregnancy category:Â
Pharmacology:Â
tranylcypromine is a monoamine oxidase inhibitor (MAOI) that irreversibly inhibits the activity of monoamine oxidase (MAO) enzymes, specifically MAO-A and MAO-B, in the central nervous system. These enzymes break down neurotransmitters such as serotonin, norepinephrine, and dopamine, which regulate mood, anxiety, and other emotional states.Â
By inhibiting the breakdown of these neurotransmitters, tranylcypromine increases their availability in the brain, leading to increased activity of these pathways and a reduction in depressive symptoms. This effect is thought to be due to the increase in the levels of these neurotransmitters, which can enhance mood, increase energy levels, and improve motivation and pleasure.Â
Pharmacodynamics:Â
The pharmacodynamics of tranylcypromine primarily involve its inhibition of monoamine oxidase (MAO) enzymes, which increases neurotransmitters such as serotonin, norepinephrine, and dopamine levels in the brain. This increase in neurotransmitter levels can have several effects on the central nervous system, including:Â
Pharmacokinetics:Â
AbsorptionÂ
tranylcypromine is rapidly and completely absorbed after oral administration, with peak plasma concentrations reached within 1-2 hours. Â
DistributionÂ
The bioavailability of tranylcypromine is approximately 100%, meaning that all the drug taken orally reaches systemic circulation.Â
It is highly bound to plasma proteins, with approximately 90% of the drug bound to albumin.Â
MetabolismÂ
tranylcypromine is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily by the CYP2A6 and CYP2C19 enzymes. The primary metabolite is phenylacetic acid, which is excreted in the urine. Other metabolites include amphetamine and methamphetamine, which can lead to false positive results in drug tests.Â
Elimination and ExcretionÂ
tranylcypromine has a short elimination half-life of around 2-3 hours, but its effects can persist for several weeks due to its irreversible inhibition of monoamine oxidase enzymes. As new MAO enzymes are synthesized, the effects of tranylcypromine will gradually dissipate, although this process may take several weeks.Â
tranylcypromine is eliminated primarily by renal excretion of its metabolites, with approximately 60-70% of the dose excreted in the urine within 24 hours. The remaining 30-40% is excreted in the feces.Â
tranylcypromine has a low volume of distribution, indicating that it is primarily distributed in the plasma and extracellular fluid.
Administration:Â
tranylcypromine is typically administered orally as a tablet or capsule, with doses ranging from 10 to 60 mg daily. The recommended starting dose is usually 10 mg once or twice a day, gradually increasing over several weeks to a maximum of 60 mg per day if needed.Â
tranylcypromine should be taken with food to reduce the risk of gastrointestinal side effects. It is essential to avoid foods and beverages that contain high levels of tyramine while taking tranylcypromine, as this can cause a potentially life-threatening hypertensive crisis. Foods and beverages to avoid include aged cheeses, cured meats, pickled or fermented foods, beer, red wine, and certain fruits and vegetables.Â
tranylcypromine should be used with caution in patients with cardiovascular disease, hypertension, or seizure disorders, as it can cause an increase in blood pressure or worsen seizures. It should also be used cautiously in patients taking other medications that can interact with tranylcypromine, such as other MAO inhibitors, sympathomimetic agents, and certain antidepressants.Â
tranylcypromine should not be abruptly discontinued, as this can lead to withdrawal symptoms such as depression, anxiety, and insomnia. Instead, the dose should be gradually tapered off over several weeks under the supervision of a healthcare provider.Â
Patient information leafletÂ
Generic Name:Â tranylcypromineÂ
Pronounced: TRAN-il-SIP-roe-meenÂ
Why do we use tranylcypromine?Â
tranylcypromine is used primarily as an antidepressant medication for treating major depressive disorder, particularly when other antidepressants have been ineffective or poorly tolerated. It is a member of the class of drugs known as monoamine oxidase inhibitors (MAOIs), which work by inhibiting the enzyme monoamine oxidase (MAO), thereby increasing neurotransmitter levels such as serotonin, norepinephrine, and dopamine in the brain. tranylcypromine has also been used off-label to treat other conditions, such as anxiety, panic, and social phobia. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
